The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has authorized the use of Eylea (aflibercept 8mg, 114.3 ...
A UK-listed biotechnology company developing inhaled and targeted delivery technologies intended to improve the performance ...
US pharma giant Pfizer (NYSE: PFE) has struck a commercialization deal with China’s Sciwind Biosciences for the GLP-1 drug Xianyida (ecnoglutide), gaining exclusive rights in mainland China in a pact ...
The US Food and Drug Administration (FDA) has granted full approval to pharma giant Pfizer’s Braftovi (encorafenib) in combination with cetuximab (marketed as Erbitux) and fluorouracil-based ...
ViiV Healthcare, the HIV specialist majority owned by GSK, has announced week 96 and end of study results from the Phase I/II IMPAACT 2017 study, the first trial to evaluate a complete injectable long ...
US biotech Generate Biomedicines has set terms for a proposed Nasdaq listing that could raise up to $425 million, as it moves to finance two Phase III asthma trials for its lead antibody. The company ...
US pharma major AbbVie’s $100 billion agreement with the US administration signals a structural recalibration of drug pricing negotiations, tying tariff exemptions and pricing flexibility directly to ...
Japan’s Astellas Pharma and USA-based Vir Biotechnology have entered into a global strategic collaboration to advance VIR-5500, an investigational PRO-XTEN dual-masked CD3 T-cell engager (TCE) ...
Denmark’s Novo Nordisk has announced—effective January 1, 2027—a lower $675 US list price, or wholesale acquisition cost (WAC), for Wegovy (semaglutide) injection 2.4mg and tablets 25mg, Ozempic ...
US biotech Slate Medicines has launched with $130 million in series A funding to advance an experimental migraine antibody licensed from China-based DartsBio Pharmaceuticals into the clinic next year.
Latin American specialty pharma company SteinCares has signed a licensing agreement with India’s Shilpa Biologicals to commercialize a biosimilar across Latin America, marking the Indian group’s first ...
Privately-held US firm Abcuro has announced topline results from the Phase II/III MUSCLE study of ulviprubart (ABC008).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results